5cd5 › Citations

Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor.

Kong L, Ju B, Chen Y, He L, Ren L, Liu J, Hong K, Su B, Wang Z, Ozorowski G, Ji X, Hua Y, Chen Y, Deller MC, Hao Y, Feng Y, Garces F, Wilson R, Dai K, O'Dell S, McKee K, Mascola JR, Ward AB, Wyatt RT, Li Y, Wilson IA, Zhu J, Shao Y
Immunity 44 939-50 (2016)
Cited: 60 times
EuropePMC logo PMID: 27067056

Abstract

VRC01-class antibodies neutralize diverse HIV-1 strains by targeting the conserved CD4-binding site. Despite extensive investigations, crucial events in the early stage of VRC01 development remain elusive. We demonstrated how VRC01-class antibodies emerged in a Chinese donor by antigen-specific single B cell sorting, structural and functional studies, and longitudinal antibody and virus repertoire analyses. A monoclonal antibody DRVIA7 with modest neutralizing breadth was isolated that displayed a subset of VRC01 signatures. X-ray and EM structures revealed a VRC01-like angle of approach, but less favorable interactions between the DRVIA7 light-chain CDR1 and the N terminus with N276 and V5 glycans of gp120. Although the DRVIA7 lineage was unable to acquire broad neutralization, longitudinal analysis revealed a repertoire-encoded VRC01 light-chain CDR3 signature and VRC01-like neutralizing heavy-chain precursors that rapidly matured within 2 years. Thus, light chain accommodation of the glycan shield should be taken into account in vaccine design targeting this conserved site of vulnerability.

Articles - 5cd5 mentioned but not cited (2)

  1. Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor. Kong L, Ju B, Chen Y, He L, Ren L, Liu J, Hong K, Su B, Wang Z, Ozorowski G, Ji X, Hua Y, Chen Y, Deller MC, Hao Y, Feng Y, Garces F, Wilson R, Dai K, O'Dell S, McKee K, Mascola JR, Ward AB, Wyatt RT, Li Y, Wilson IA, Zhu J, Shao Y. Immunity 44 939-950 (2016)
  2. Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains. Wang J, Erazo T, Ferguson FM, Buckley DL, Gomez N, Muñoz-Guardiola P, Diéguez-Martínez N, Deng X, Hao M, Massefski W, Fedorov O, Offei-Addo NK, Park PM, Dai L, DiBona A, Becht K, Kim ND, McKeown MR, Roberts JM, Zhang J, Sim T, Alessi DR, Bradner JE, Lizcano JM, Blacklow SC, Qi J, Xu X, Gray NS. ACS Chem Biol 13 2438-2448 (2018)


Reviews citing this publication (11)

  1. Identification and specificity of broadly neutralizing antibodies against HIV. McCoy LE, Burton DR. Immunol. Rev. 275 11-20 (2017)
  2. Antigenic landscape of the HIV-1 envelope and new immunological concepts defined by HIV-1 broadly neutralizing antibodies. Wu X, Kong XP. Curr. Opin. Immunol. 42 56-64 (2016)
  3. Coevolution of HIV-1 and broadly neutralizing antibodies. Doria-Rose NA, Landais E. Curr Opin HIV AIDS 14 286-293 (2019)
  4. Stabilized HIV-1 envelope glycoprotein trimers for vaccine use. Medina-Ramírez M, Sanders RW, Sattentau QJ. Curr Opin HIV AIDS 12 241-249 (2017)
  5. Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success. Jaworski JP, Vendrell A, Chiavenna SM. Front Immunol 7 661 (2016)
  6. Design Concepts of Virus-Like Particle-Based HIV-1 Vaccines. Chen CW, Saubi N, Joseph-Munné J. Front Immunol 11 573157 (2020)
  7. Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers. Landais E, Moore PL. Retrovirology 15 61 (2018)
  8. Recent Progress toward Engineering HIV-1-Specific Neutralizing Monoclonal Antibodies. Sun M, Li Y, Zheng H, Shao Y. Front Immunol 7 391 (2016)
  9. Development of an HIV vaccine using a vesicular stomatitis virus vector expressing designer HIV-1 envelope glycoproteins to enhance humoral responses. Racine T, Kobinger GP, Arts EJ. AIDS Res Ther 14 55 (2017)
  10. Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem. Verkoczy L. Adv. Immunol. 134 235-352 (2017)
  11. The expanding array of HIV broadly neutralizing antibodies. McCoy LE. Retrovirology 15 70 (2018)

Articles citing this publication (47)

  1. Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies. Briney B, Sok D, Jardine JG, Kulp DW, Skog P, Menis S, Jacak R, Kalyuzhniy O, de Val N, Sesterhenn F, Le KM, Ramos A, Jones M, Saye-Francisco KL, Blane TR, Spencer S, Georgeson E, Hu X, Ozorowski G, Adachi Y, Kubitz M, Sarkar A, Wilson IA, Ward AB, Nemazee D, Burton DR, Schief WR. Cell 166 1459-1470.e11 (2016)
  2. Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires. Tian M, Cheng C, Chen X, Duan H, Cheng HL, Dao M, Sheng Z, Kimble M, Wang L, Lin S, Schmidt SD, Du Z, Joyce MG, Chen Y, DeKosky BJ, Chen Y, Normandin E, Cantor E, Chen RE, Doria-Rose NA, Zhang Y, Shi W, Kong WP, Choe M, Henry AR, Laboune F, Georgiev IS, Huang PY, Jain S, McGuire AT, Georgeson E, Menis S, Douek DC, Schief WR, Stamatatos L, Kwong PD, Shapiro L, Haynes BF, Mascola JR, Alt FW. Cell 166 1471-1484.e18 (2016)
  3. Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C. Klasse PJ, LaBranche CC, Ketas TJ, Ozorowski G, Cupo A, Pugach P, Ringe RP, Golabek M, van Gils MJ, Guttman M, Lee KK, Wilson IA, Butera ST, Ward AB, Montefiori DC, Sanders RW, Moore JP. PLoS Pathog. 12 e1005864 (2016)
  4. Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. Medina-Ramírez M, Garces F, Escolano A, Skog P, de Taeye SW, Del Moral-Sanchez I, McGuire AT, Yasmeen A, Behrens AJ, Ozorowski G, van den Kerkhof TLGM, Freund NT, Dosenovic P, Hua Y, Gitlin AD, Cupo A, van der Woude P, Golabek M, Sliepen K, Blane T, Kootstra N, van Breemen MJ, Pritchard LK, Stanfield RL, Crispin M, Ward AB, Stamatatos L, Klasse PJ, Moore JP, Nemazee D, Nussenzweig MC, Wilson IA, Sanders RW. J. Exp. Med. 214 2573-2590 (2017)
  5. An MPER antibody neutralizes HIV-1 using germline features shared among donors. Zhang L, Irimia A, He L, Landais E, Rantalainen K, Leaman DP, Vollbrecht T, Stano A, Sands DI, Kim AS, IAVI Protocol G Investigators, Poignard P, Burton DR, Murrell B, Ward AB, Zhu J, Wilson IA, Zwick MB. Nat Commun 10 5389 (2019)
  6. Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller. Freund NT, Wang H, Scharf L, Nogueira L, Horwitz JA, Bar-On Y, Golijanin J, Sievers SA, Sok D, Cai H, Cesar Lorenzi JC, Halper-Stromberg A, Toth I, Piechocka-Trocha A, Gristick HB, van Gils MJ, Sanders RW, Wang LX, Seaman MS, Burton DR, Gazumyan A, Walker BD, West AP, Bjorkman PJ, Nussenzweig MC. Sci Transl Med 9 (2017)
  7. B cells expressing authentic naive human VRC01-class BCRs can be recruited to germinal centers and affinity mature in multiple independent mouse models. Huang D, Abbott RK, Havenar-Daughton C, Skog PD, Al-Kolla R, Groschel B, Blane TR, Menis S, Tran JT, Thinnes TC, Volpi SA, Liguori A, Schiffner T, Villegas SM, Kalyuzhniy O, Pintea M, Voss JE, Phelps N, Tingle R, Rodriguez AR, Martin G, Kupryianov S, deCamp A, Schief WR, Nemazee D, Crotty S. Proc Natl Acad Sci U S A 117 22920-22931 (2020)
  8. Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth. Chen X, Zhou T, Schmidt SD, Duan H, Cheng C, Chuang GY, Gu Y, Louder MK, Lin BC, Shen CH, Sheng Z, Zheng MX, Doria-Rose NA, Joyce MG, Shapiro L, Tian M, Alt FW, Kwong PD, Mascola JR. Immunity 54 324-339.e8 (2021)
  9. Virus-driven Inflammation Is Associated With the Development of bNAbs in Spontaneous Controllers of HIV. Dugast AS, Arnold K, Lofano G, Moore S, Hoffner M, Simek M, Poignard P, Seaman M, Suscovich TJ, Pereyra F, Walker BD, Lauffenburger D, Kwon DS, Keele BF, Alter G. Clin. Infect. Dis. 64 1098-1104 (2017)
  10. Functional convergence of a germline-encoded neutralizing antibody response in rhesus macaques immunized with HCV envelope glycoproteins. Chen F, Tzarum N, Lin X, Giang E, Velázquez-Moctezuma R, Augestad EH, Nagy K, He L, Hernandez M, Fouch ME, Grinyó A, Chavez D, Doranz BJ, Prentoe J, Stanfield RL, Lanford R, Bukh J, Wilson IA, Zhu J, Law M. Immunity 54 781-796.e4 (2021)
  11. A broadly neutralizing antibody protects Syrian hamsters against SARS-CoV-2 Omicron challenge. Zhou B, Zhou R, Tang B, Chan JF, Luo M, Peng Q, Yuan S, Liu H, Mok BW, Chen B, Wang P, Poon VK, Chu H, Chan CC, Tsang JO, Chan CC, Au KK, Man HO, Lu L, To KK, Chen H, Yuen KY, Dang S, Chen Z. Nat Commun 13 3589 (2022)
  12. Improving the Expression and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers by Targeted Sequence Changes. Ringe RP, Ozorowski G, Yasmeen A, Cupo A, Cruz Portillo VM, Pugach P, Golabek M, Rantalainen K, Holden LG, Cottrell CA, Wilson IA, Sanders RW, Ward AB, Klasse PJ, Moore JP. J. Virol. 91 (2017)
  13. Effects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction. Crooks ET, Osawa K, Tong T, Grimley SL, Dai YD, Whalen RG, Kulp DW, Menis S, Schief WR, Binley JM. Virology 505 193-209 (2017)
  14. Design of immunogens to elicit broadly neutralizing antibodies against HIV targeting the CD4 binding site. Conti S, Kaczorowski KJ, Song G, Porter K, Andrabi R, Burton DR, Chakraborty AK, Karplus M. Proc Natl Acad Sci U S A 118 e2018338118 (2021)
  15. Differential Antibody Responses to Conserved HIV-1 Neutralizing Epitopes in the Context of Multivalent Scaffolds and Native-Like gp140 Trimers. Morris CD, Azadnia P, de Val N, Vora N, Honda A, Giang E, Saye-Francisco K, Cheng Y, Lin X, Mann CJ, Tang J, Sok D, Burton DR, Law M, Ward AB, He L, Zhu J. MBio 8 (2017)
  16. Hidden Lineage Complexity of Glycan-Dependent HIV-1 Broadly Neutralizing Antibodies Uncovered by Digital Panning and Native-Like gp140 Trimer. He L, Lin X, de Val N, Saye-Francisco KL, Mann CJ, Augst R, Morris CD, Azadnia P, Zhou B, Sok D, Ozorowski G, Ward AB, Burton DR, Zhu J. Front Immunol 8 1025 (2017)
  17. The glycan-mediated mechanism on the interactions of gp120 with CD4 and antibody: Insights from molecular dynamics simulation. Zhang Y, Niu Y, Tian J, Liu X, Yao X, Liu H. Chem Biol Drug Des 90 1237-1246 (2017)
  18. Identification of a novel HIV-1-neutralizing antibody from a CRF07_BC-infected Chinese donor. Sun Y, Qiao Y, Zhu Y, Chong H, He Y. Oncotarget 8 63047-63063 (2017)
  19. Functional development of a V3/glycan-specific broadly neutralizing antibody isolated from a case of HIV superinfection. Shipley MM, Mangala Prasad V, Doepker LE, Dingens A, Ralph DK, Harkins E, Dhar A, Arenz D, Chohan V, Weight H, Mandaliya K, Bloom JD, Matsen FA, Lee KK, Overbaugh JM. Elife 10 e68110 (2021)
  20. Genetic and structural insights into broad neutralization of hepatitis C virus by human VH1-69 antibodies. Tzarum N, Giang E, Kong L, He L, Prentoe J, Augestad E, Hua Y, Castillo S, Lauer GM, Bukh J, Zhu J, Wilson IA, Law M. Sci Adv 5 eaav1882 (2019)
  21. Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer and a glycosylated HIV-1 gp120 core. Borst AJ, Weidle CE, Gray MD, Frenz B, Snijder J, Joyce MG, Georgiev IS, Stewart-Jones GB, Kwong PD, McGuire AT, DiMaio F, Stamatatos L, Pancera M, Veesler D. Elife 7 (2018)
  22. Neutralizing Antibodies Induced by First-Generation gp41-Stabilized HIV-1 Envelope Trimers and Nanoparticles. Kumar S, Lin X, Ngo T, Shapero B, Sou C, Allen JD, Copps J, Zhang L, Ozorowski G, He L, Crispin M, Ward AB, Wilson IA, Zhu J. mBio 12 e0042921 (2021)
  23. Time-course, negative-stain electron microscopy-based analysis for investigating protein-protein interactions at the single-molecule level. Nogal B, Bowman CA, Ward AB. J. Biol. Chem. 292 19400-19410 (2017)
  24. Virus Evolution and Neutralization Sensitivity in an HIV-1 Subtype B' Infected Plasma Donor with Broadly Neutralizing Activity. Hu Y, Zou S, Wang Z, Liu Y, Ren L, Hao Y, Sun S, Hu X, Ruan Y, Ma L, Shao Y, Hong K. Vaccines (Basel) 9 311 (2021)
  25. A SARS-CoV-2 neutralizing antibody discovery by single cell sequencing and molecular modeling. Wang Z, Tang Q, Liu B, Zhang W, Chen Y, Ji N, Peng Y, Yang X, Cui D, Kong W, Tang X, Yang T, Zhang M, Chang X, Zhu J, Huang M, Feng Z. J Biomed Res 37 166-178 (2022)
  26. A VH1-69 antibody lineage from an infected Chinese donor potently neutralizes HIV-1 by targeting the V3 glycan supersite. Kumar S, Ju B, Shapero B, Lin X, Ren L, Zhang L, Li D, Zhou Z, Feng Y, Sou C, Mann CJ, Hao Y, Sarkar A, Hou J, Nunnally C, Hong K, Wang S, Ge X, Su B, Landais E, Sok D, Zwick MB, He L, Zhu J, Wilson IA, Shao Y. Sci Adv 6 (2020)
  27. A diverse collection of B cells responded to HIV infection in infant BG505. Simonich C, Shipley MM, Doepker L, Gobillot T, Garrett M, Cale EM, Hennessy B, Itell H, Chohan V, Doria-Rose N, Nduati R, Overbaugh J. Cell Rep Med 2 100314 (2021)
  28. Bibliometric and visualized analysis of elite controllers based on CiteSpace: landscapes, hotspots, and frontiers. Yuan X, Lai Y. Front Cell Infect Microbiol 13 1147265 (2023)
  29. Characteristics of Envelope Genes in a Chinese Chronically HIV-1 Infected Patient With Broadly Neutralizing Activity. Zhang D, Zou S, Hu Y, Hou J, Hu X, Ren L, Ma L, He X, Shao Y, Hong K. Front Microbiol 10 1096 (2019)
  30. Characterization of RBD-specific cross-neutralizing antibodies responses against SARS-CoV-2 variants from COVID-19 convalescents. Wang Z, Li D, Chen Y, Sun Y, Jin C, Hu C, Feng Y, Su J, Ren L, Hao Y, Wang S, Zhu M, Liu Y, Qi J, Zhu B, Shao Y. Front Immunol 14 1160283 (2023)
  31. Complementary Roles of Antibody Heavy and Light Chain Somatic Hypermutation in Conferring Breadth and Potency to the HIV-1-Specific CAP256-VRC26 bNAb Lineage. Sacks D, Wiehe K, Morris L, Moore PL. J Virol 96 e0027022 (2022)
  32. Development of a Potent and Protective Germline-Like Antibody Lineage Against Zika Virus in a Convalescent Human. Gao F, Lin X, He L, Wang R, Wang H, Shi X, Zhang F, Yin C, Zhang L, Zhu J, Yu L. Front Immunol 10 2424 (2019)
  33. Estimation of the breadth of CD4bs targeting HIV antibodies by molecular modeling and machine learning. Conti S, Karplus M. PLoS Comput. Biol. 15 e1006954 (2019)
  34. Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions. Caniels TG, Medina-Ramírez M, Zhang J, Sarkar A, Kumar S, LaBranche A, Derking R, Allen JD, Snitselaar JL, Capella-Pujol J, Sánchez IDM, Yasmeen A, Diaz M, Aldon Y, Bijl TPL, Venkatayogi S, Martin Beem JS, Newman A, Jiang C, Lee WH, Pater M, Burger JA, van Breemen MJ, de Taeye SW, Rantalainen K, LaBranche C, Saunders KO, Montefiori D, Ozorowski G, Ward AB, Crispin M, Moore JP, Klasse PJ, Haynes BF, Wilson IA, Wiehe K, Verkoczy L, Sanders RW. Cell Rep Med 4 101003 (2023)
  35. HIV-1 gp120-CD4-Induced Antibody Complex Elicits CD4 Binding Site-Specific Antibody Response in Mice. Galkin A, Chen Y, Guenaga J, O'Dell S, Acevedo R, Steinhardt JJ, Wang Y, Wilson R, Chiang CI, Doria-Rose N, Grishaev AV, Mascola JR, Li Y. J Immunol 204 1543-1561 (2020)
  36. Highly mutated antibodies capable of neutralizing N276 glycan-deficient HIV after a single immunization with an Env trimer. Lee JH, Nakao C, Appel M, Le A, Landais E, Kalyuzhniy O, Hu X, Liguori A, Mullen TM, Groschel B, Abbott RK, Sok D, Schief WR, Crotty S. Cell Rep 38 110485 (2022)
  37. Identification of a novel broadly HIV-1-neutralizing antibody from a CRF01_AE-infected Chinese donor. Ju B, Li D, Ren L, Hou J, Hao Y, Liang H, Wang S, Zhu J, Wei M, Shao Y. Emerg Microbes Infect 7 174 (2018)
  38. Infection with wild-type SARS-CoV-2 elicits broadly neutralizing and protective antibodies against omicron subvariants. Ju B, Zhang Q, Wang Z, Aw ZQ, Chen P, Zhou B, Wang R, Ge X, Lv Q, Cheng L, Zhang R, Wong YH, Chen H, Wang H, Shan S, Liao X, Shi X, Liu L, Chu JJH, Wang X, Zhang Z, Zhang L. Nat Immunol 24 690-699 (2023)
  39. Omicron BQ.1.1 and XBB.1 unprecedentedly escape broadly neutralizing antibodies elicited by prototype vaccination. Ju B, Fan Q, Liu C, Shen S, Wang M, Guo H, Zhou B, Ge X, Zhang Z. Cell Rep 42 112532 (2023)
  40. Quantitative evaluation of protective antibody response induced by hepatitis E vaccine in humans. Wen GP, He L, Tang ZM, Wang SL, Zhang X, Chen YZ, Lin X, Liu C, Chen JX, Ying D, Chen ZH, Wang YB, Luo WX, Huang SJ, Li SW, Zhang J, Zheng ZZ, Zhu J, Xia NS. Nat Commun 11 3971 (2020)
  41. Rapid and Focused Maturation of a VRC01-Class HIV Broadly Neutralizing Antibody Lineage Involves Both Binding and Accommodation of the N276-Glycan. Umotoy J, Bagaya BS, Joyce C, Schiffner T, Menis S, Saye-Francisco KL, Biddle T, Mohan S, Vollbrecht T, Kalyuzhniy O, Madzorera S, Kitchin D, Lambson B, Nonyane M, Kilembe W, IAVI Protocol C Investigators, IAVI African HIV Research Network, Poignard P, Schief WR, Burton DR, Murrell B, Moore PL, Briney B, Sok D, Landais E. Immunity 51 141-154.e6 (2019)
  42. SARS-CoV-2 hijacks neutralizing dimeric IgA for nasal infection and injury in Syrian hamsters1. Zhou B, Zhou R, Chan JF, Zeng J, Zhang Q, Yuan S, Liu L, Robinot R, Shan S, Liu N, Ge J, Kwong HY, Zhou D, Xu H, Chan CC, Poon VK, Chu H, Yue M, Kwan KY, Chan CY, Chan CC, Chik KK, Du Z, Au KK, Huang H, Man HO, Cao J, Li C, Wang Z, Zhou J, Song Y, Yeung ML, To KK, Ho DD, Chakrabarti LA, Wang X, Zhang L, Yuen KY, Chen Z. Emerg Microbes Infect 12 2245921 (2023)
  43. SEPPA 3.0-enhanced spatial epitope prediction enabling glycoprotein antigens. Zhou C, Chen Z, Zhang L, Yan D, Mao T, Tang K, Qiu T, Cao Z. Nucleic Acids Res. 47 W388-W394 (2019)
  44. Single-component multilayered self-assembling protein nanoparticles presenting glycan-trimmed uncleaved prefusion optimized envelope trimmers as HIV-1 vaccine candidates. Zhang YN, Paynter J, Antanasijevic A, Allen JD, Eldad M, Lee YZ, Copps J, Newby ML, He L, Chavez D, Frost P, Goodroe A, Dutton J, Lanford R, Chen C, Wilson IA, Crispin M, Ward AB, Zhu J. Nat Commun 14 1985 (2023)
  45. Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies. Cottrell CA, Manne K, Kong R, Wang S, Zhou T, Chuang GY, Edwards RJ, Henderson R, Janowska K, Kopp M, Lin BC, Louder MK, Olia AS, Rawi R, Shen CH, Taft JD, Torres JL, Wu NR, Zhang B, Doria-Rose NA, Cohen MS, Haynes BF, Shapiro L, Ward AB, Acharya P, Mascola JR, Kwong PD. Cell Rep 37 109922 (2021)
  46. Structural insights into broadly neutralizing antibodies elicited by hybrid immunity against SARS-CoV-2. Luo M, Zhou B, Reddem ER, Tang B, Chen B, Zhou R, Liu H, Liu L, Katsamba PS, Au KK, Man HO, To KK, Yuen KY, Shapiro L, Dang S, Ho DD, Chen Z. Emerg Microbes Infect 12 2146538 (2023)
  47. Using B cell receptor lineage structures to predict affinity. Ralph DK, Matsen FA. PLoS Comput Biol 16 e1008391 (2020)


Quick links